Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum

Vaxart (OTCQX: VXRT) will showcase its oral vaccine platform and strategic vision at the 2026 Taiwan Biotech Forum and BIO International Convention in San Diego.

Rhea-AI Summary

Vaxart (OTCQX: VXRT) will showcase its oral vaccine platform and strategic vision at the 2026 Taiwan Biotech Forum and BIO International Convention in San Diego.

Company leaders will discuss targeting mucosal immunity with oral tablets, which may reduce reliance on injections and cold-chain logistics.

Argus Jun 15 session

+2.68% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – VXRT

On Jun 15, the day this news came out, VXRT closed 2.68% above the previous close.

Data tracked by StockTitan Argus for the Jun 15 session.

Key Figures

BIO 2026 dates: June 22–25, 2026 Taiwan Biotech Forum time: 1:30pm–5:30pm PT BIO presentation time: 3:15pm–3:35pm PT +1 more

BIO 2026 dates

June 22–25, 2026

BIO International Convention schedule

Taiwan Biotech Forum time

1:30pm–5:30pm PT

Session with CSO Sean Tucker, Ph.D.

BIO presentation time

3:15pm–3:35pm PT

Storytelling Stage presentation by CEO and CSO

Storytelling Stage booth

Booth #3035

Location of BIO International Convention presentation

Historical Context

5 past events · Latest: Jun 09

5 events

1. Jun 09

   Conference participation

   24h Move

   -1.5%

   Announcement of participation in BTIG Infectious Disease Day 2026.

2. Jun 08

   Proxy campaign letter

   24h Move

   -5.4%

   Company urges shareholders to back board slate amid proxy contest.

3. Jun 01

   Definitive proxy filed

   24h Move

   -2.3%

   Definitive proxy and shareholder letter on governance and pipeline.

4. May 19

   Prelim proxy & letter

   24h Move

   -1.6%

   Preliminary proxy and open letter ahead of contested annual meeting.

5. May 07

   Earnings & update

   24h Move

   -5.4%

   Q1 2026 results with revenue, net income, and cash runway to Q2 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

oral recombinant vaccines, precision medicine, mucosal immunity, cold-chain logistics

4 terms

oral recombinant vaccines medical

"developing a range of oral recombinant vaccines based on its proprietary delivery platform"

Oral recombinant vaccines are medicines taken by mouth that use harmless, genetically engineered material to show the immune system a safe version of a disease marker, similar to teaching a security system to recognize a fake badge instead of the real intruder. They matter to investors because delivering vaccines as a pill can cut distribution costs, improve uptake and storage, and speed manufacturing scale-up, but also carries development and regulatory risks that affect commercial value.

precision medicine medical

"panel discussing innovative therapeutic modalities in precision medicine"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

mucosal immunity medical

"highlight how targeting mucosal immunity via an oral pill could eliminate reliance"

The immune protection found on the body's moist surfaces—like the nose, throat, lungs, and gut—that acts as the first line of defense against infections by trapping or neutralizing pathogens before they enter deeper tissues. Investors care because products that boost or target this frontline defense (for example, nasal sprays or oral vaccines) can change how well diseases are prevented or treated, shaping market demand, regulatory approval chances, and revenue potential for health companies.

cold-chain logistics technical

"could eliminate reliance on traditional needle injections and cold-chain logistics"

Cold-chain logistics is the storage and transport system that keeps temperature-sensitive products (like vaccines, biologics, food, or chemicals) within strict temperature ranges from production to end use, using refrigerated trucks, insulated packaging, climate-controlled warehouses and continuous temperature monitoring. It matters to investors because failures can spoil products, trigger recalls, or block sales, affecting revenue, regulatory risk and margins—think of it as a refrigerated relay race where a single broken link can destroy value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.

2026 Taiwan Biotech Forum
Date: Sunday, June 21, 2026
Location: The Westin San Diego Gaslamp Quarter
Time: 1:30pm – 5:30pm PT
Sean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision medicine.

2026 BIO International Convention
Date: Tuesday, June 23, 2026
Location: San Diego Convention Center, Storytelling Stage (Booth #3035)
Time: 3:15pm – 3:35pm PT
Steve Lo, Chief Executive Officer, and Dr. Tucker will present on the innovation, development and consumer friendly approach of the company’s oral vaccine tablet platform. The discussion will highlight how targeting mucosal immunity via an oral pill could eliminate reliance on traditional needle injections and cold-chain logistics, offering a modern solution to improve global health equity and pandemic readiness.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What events will Vaxart (VXRT) attend during BIO 2026 in San Diego?

Vaxart will participate in the 2026 Taiwan Biotech Forum and present at the BIO International Convention Storytelling Stage. According to Vaxart, both events occur in San Diego alongside BIO 2026 in late June 2026.

When and where is Vaxart presenting at the 2026 Taiwan Biotech Forum?

Vaxart will take part in the 2026 Taiwan Biotech Forum on June 21, 2026, at The Westin San Diego Gaslamp Quarter. According to Vaxart, the session runs from 1:30pm to 5:30pm PT.

What will Vaxart (VXRT) present at the 2026 BIO International Convention?

Vaxart will present its oral vaccine tablet platform on June 23, 2026, at the Storytelling Stage, Booth 3035. According to Vaxart, the talk runs from 3:15pm to 3:35pm PT and covers innovation and development.

Who from Vaxart will speak at BIO 2026 and the Taiwan Biotech Forum?

Chief Scientific Officer Sean Tucker will join a precision medicine panel at the Taiwan Biotech Forum. According to Vaxart, CEO Steve Lo and Dr. Tucker will jointly present the oral vaccine platform at the BIO International Convention.

What is Vaxart’s oral vaccine platform and why is it important for investors?

Vaxart is developing oral recombinant vaccines delivered as tablets that target mucosal immunity. According to Vaxart, this approach could lessen dependence on needle injections and cold-chain logistics, potentially improving access, pandemic readiness, and global health equity.

How could Vaxart’s oral tablet vaccines impact global health equity and pandemic readiness?

Vaxart believes oral vaccine tablets may simplify distribution by reducing injection and cold-chain needs. According to Vaxart, targeting mucosal immunity through pills could support broader vaccination coverage, supporting global health equity and future pandemic readiness if development progresses successfully.